Ismail T, Angrisani L, Gunson B K, Hübscher S G, Buckels J A, Neuberger J M, Elias E, McMaster P
Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
Br J Surg. 1990 Sep;77(9):983-7. doi: 10.1002/bjs.1800770908.
Between January 1982 and April 1989, 134 patients with a suspected liver neoplasm were referred to the liver unit, Queen Elizabeth Hospital, Birmingham. In 105 (78 per cent), a primary hepatic neoplasm was histologically confirmed, and 47 patients (45 per cent) proved to have primary hepatocellular carcinoma. Twenty-nine orthotopic liver transplants were performed in 28 of these patients (27 per cent). Twenty patients (71 per cent) survived 30 days or longer (median 11.5 months; range 2-87 months), of whom nine are currently alive. We retrospectively analysed our data to determine the influence of preoperative evaluation, histological type and staging on outcome. Computed tomography proved to be superior to intraoperative assessment (86 versus 58 per cent) in diagnosing tumour positive nodes. Patients with tumour negative lymphadenopathy had a better prognosis. Postoperative stage I/II had a median survival of 16 months (range 3-87 months) compared with 7.5 months (range 2-20 months) for stage III. Non-cirrhotic patients with hepatocellular carcinoma had the best prognosis; cholangiocellular carcinoma and cirrhotic patients with hepatocelluar carcinoma had the worst outcome with no survivors beyond 1 year. Because of the advanced stage of disease at the time of presentation, the value of liver transplantation in primary liver cancer is limited. For those presenting with advanced disease confined to the liver (stage I/II) in whom conventional hepatic resection is not possible, significant benefit can be achieved in selected cases.
1982年1月至1989年4月期间,134例疑似肝脏肿瘤患者被转诊至伯明翰伊丽莎白女王医院肝脏科。其中105例(78%)经组织学确诊为原发性肝脏肿瘤,47例(45%)被证实为原发性肝细胞癌。28例患者(27%)接受了29次原位肝移植。20例患者(71%)存活30天或更长时间(中位生存期11.5个月;范围2 - 87个月),其中9例目前仍存活。我们对数据进行了回顾性分析,以确定术前评估、组织学类型和分期对预后的影响。计算机断层扫描在诊断肿瘤阳性淋巴结方面优于术中评估(分别为86%和58%)。无肿瘤转移淋巴结的患者预后较好。术后I/II期患者的中位生存期为16个月(范围3 - 87个月),而III期患者为7.5个月(范围2 - 20个月)。非肝硬化的肝细胞癌患者预后最佳;胆管细胞癌以及肝硬化的肝细胞癌患者预后最差,无一例存活超过1年。由于就诊时疾病已处于晚期,肝移植在原发性肝癌中的价值有限。对于那些就诊时疾病局限于肝脏(I/II期)且无法进行传统肝切除的患者,在部分病例中可获得显著益处。